Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: The life study

Journal of the American College of Cardiology

Volumn 43, Issue 6, 2004, Pages 1047-1055

  Julius, Stevo ^a   Alderman, Michael H ^b   Beevers, Gareth ^c   Dahlöf, Björn ^d   Devereux, Richard B ^e   Douglas, Janice G ^f   Edelman, Jonathan M ^g   Harris, Katherine E ^g   Kjeldsen, Sverre E ^a,h   Nesbitt, Shawna ⁱ   Randall, Otelio S ^j   Wright Jr , Jackson T ^f  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c CITY HOSPITAL   (United Kingdom)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e WEILL CORNELL MEDICAL CENTER   (United States)

^f CASE WESTERN RESERVE UNIVERSITY   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

^h ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^j HOWARD UNIVERSITY HOSPITAL   (United States)

more..

Author keywords

ACE; ALLHAT; Angiotensin converting enzyme; Antihypertensive therapy and Lipid Lowering Heart Attack prevention Trial; Blood pressure; BP; CHD; CI; Confidence interval; Coronary heart disease; ECG; Electrocardiogram electrocardiographic; ISH

Indexed keywords

ANGIOTENSIN ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LOSARTAN; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ELECTROCARDIOGRAPHY; ETHNIC GROUP; FEMALE; HAZARD ASSESSMENT; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SINGLE BLIND PROCEDURE; STROKE; TREATMENT OUTCOME;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; ATENOLOL; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED; TREATMENT OUTCOME; UNITED STATES;

EID: 12144290821     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.11.029     Document Type: Article

References (23)

1. LIFE Study Group, Dahlöf B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) A randomised trial against atenolol. Lancet. 359:2002;995-1003.
2. LIFE Study Group, Lindholm L.H., Ibsen H., Dahlöf B., et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) A randomised trial against atenolol. Lancet. 359:2002;1004-1010.
3. LIFE Study Group, Kjeldsen S.E., Dahlöf B., Devereux R.B., et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA. 288:2002;1491-1498.
4. LIFE Study Group, Dahlöf B., Devereux R., de Faire U., et al. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study Rationale, design, and methods. Am J Hypertens. 10:1997;705-713.
5. LIFE Study Group, Dahlöf B., Devereux R.B., Julius S., et al. Characteristics of 9194 patients with left ventricular hypertrophy The life study. Hypertension. 32:1998;989-997.
6. Gail M., Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics. 41:1985;361-372.
7. Schwartz R.S. Racial profiling in medical research. N Engl J Med. 344:2001;1392-1393.
8. Luft F.C., Grim C.E., Weinberger M.H. Electrolyte and volume homeostasis in blacks. Hall W.D., Saunders E., Shulman N.B. Hypertension in Blacks Epidemiology, pathophysiology and treatment. 1985;115-131 Year Book Medical Publishers, Chicago, IL.
9. Laragh JH, Sealey JE. Renin system understanding for analysis and treatment of hypertensive patients: a means to quantify the vasoconstrictor elements, diagnose curable renal and adrenal causes, assess risk of cardiovascular morbidity and find the best-fit drug regimen. In: Laragh JH, Brenner BM, editors. Hypertension Pathophysiology, Diagnosis and Management. 2nd ed. Lippincott Williams & Wilkins, 1995:1813-36.
10. Hall W.D. Pharmacologic therapy of hypertension in blacks. J Clin Hypertens. 3:(Suppl 3):1987;108S-113S.
11. Gottdiener J.S., Reda D.J., Massie B.M., Materson B.J., Williams D.W., Anderson R.J., VA Cooperative Study Group on Antihypertensive Agents. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension Comparison of six antihypertensive agents. Circulation. 95:1997;2007-2014.
12. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic The antihypertensive and lipid-lowering treatment to prevent heart attack trial (allhat). JAMA. 288:2002;2981-2997.
13. Carson P., Ziesche S., Johnson G., Cohn J.N. Racial differences in response to therapy for heart failure Analysis of the vasodilator-heart failure trials. J Card Fail. 5:1999;178-187.
14. Exner D.V., Dries D.L., Domanski M.J., Cohn J.N. Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 344:2001;1351-1357.
15. Dries D.L., Strong M.H., Cooper R.S., Drazner M.H. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol. 40:2002;311-317.
16. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 344:2001;1659-1667.
17. U.S. Carvedilol Heart Failure Study Group, Yancy C.W., Fowler M.B., Colucci W.S., et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 344:2001;1358-1365.
18. Schiffrin E.L., Park J.B., Intengan H.D., Touyz R.M. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation. 101:2000;1653-1659.
19. Hypertension in African Americans Working Group, Douglas J.G., Bakris G.L., Epstein M., et al. Management of high blood pressure in African Americans Consensus statement of the hypertension in african americans working group of the international society on hypertension in blacks. Arch Intern Med. 163:2003;525-541.
20. African American Study of Kidney Disease and Hypertension (AASK) Study Group, Agodoa L.Y., Appel L., Bakris G.L., et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis A randomized controlled trial. JAMA. 285:2001;2719-2728.
21. African American Study of Kidney Disease and Hypertension Study Group, Wright J.T., Bakris G., Greene T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease Results from the aask trial. JAMA. 288:2002;2421-2431.
22. RENAAL Study Investigators, Brenner B.M., Cooper M.E., deZeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 345:2001;861-869.
23. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group, Parving H.H., Lehnert H., Bröchner-Mortensen J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 345:2001;870-878.